Unknown

Dataset Information

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.


ABSTRACT:

Background

Recurrent malignant brain tumors (RMBTs) carry a poor prognosis. Dichloroacetate (DCA) activates mitochondrial oxidative metabolism and has shown activity against several human cancers.

Design

We conducted an open-label study of oral DCA in 15 adults with recurrent WHO grade III - IV gliomas or metastases from a primary cancer outside the central nervous system. The primary objective was detection of a dose limiting toxicity for RMBTs at 4 weeks of treatment, defined as any grade 4 or 5 toxicity, or grade 3 toxicity directly attributable to DCA, based on the National Cancer Institute's Common Toxicity Criteria for Adverse Events, version 4.0. Secondary objectives involved safety, tolerability and hypothesis-generating data on disease status. Dosing was based on ha

SUBMITTER: Dunbar EM 

PROVIDER: S-EPMC4455946 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature